Apolipoprotein A‐I: Insights from redox proteomics for its role in neurodegeneration
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Proteomics has a wide range of applications, including determination of differences in the proteome in terms of expression and post‐translational protein modifications. Redox proteomics allows the identification of specific targets of protein oxidation in a biological sample. Using proteomic techniques, apolipoprotein A‐I(Apo A‐I) has been found at decreased levels in subjects with a variety of neurodegenerative disorders including in the serum and cerebrospinal fluid (CSF) of A lzheimer disease (AD),P arkinson disease (PD), and D own syndrome (DS) with gout subjects.A po A‐I plays roles in cholesterol transport and regulation of inflammation. Redox proteomics further showed A po A‐I to be highly oxidatively modified and particularly susceptible to modification by 4‐hydroxy‐2‐trans‐nonenal (HNE), a lipid peroxidation product. In the current review, we discuss the consequences of oxidation of A po A‐I in terms of neurodegeneration.ROS‐associated chemotherapy related A po A‐I oxidation leads to elevation of peripheral levels of tumor necrosis factor‐α (TNF‐α) that can cross the blood‐brain barrier (BBB) causing a signaling cascade that can contribute to neuronal death, likely a contributor to what patients refer to as “chemobrain.” Current evidence suggests A po A‐I to be a promising diagnostic marker as well as a potential target for therapeutic strategies in these neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α
Stellwagen, D., Beattie, E. C., Seo, J. Y., & Malenka, R. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4486-04.2005 · Cited by 985 · cited 2×
“Neuronal TNFR1 also has influence over Ca2+mediated cell death by increasing the membranous expression of iontropic glutamate receptor AMPA, through the activation of IP3 [71].”
BackgroundImmunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749 · cited 1×
“Activation of microglial TNF- receptors leads to the upregulation of the glutamate generating enzyme glutaminase and subsequent extracellular release of excess glutamate through hemichannels [65].”
BackgroundApoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
Busciglio, J., & Yankner, B. A. (1995) · Nature · doi:10.1038/378776a0 · Cited by 741 · cited 1×
“Increased oxidative stress, indexed by ROS and lipid peroxidation, has been shown in DS neurons [116].”
BackgroundTNF receptor subtype signalling: Differences and cellular consequences
MacEwan, D. J. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00262-5 · Cited by 610 · cited 2×
“TNFR1, also known as the death receptor, has an intracellular death domain (DD) consisting of 80 amino acids and is located near the carboxy-terminus [59].”
BackgroundMurine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577
Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567 · cited 1×
“Cognitive decline has been correlated to soluble A oligomers rather than to insoluble A plaques [108, 109].”
BackgroundTranslating molecular discoveries into new therapies for atherosclerosis
Rader, D. J., & Daugherty, A. (2008) · Nature · doi:10.1038/nature06796 · Cited by 515
Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response
MURRAY, P. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.010 · Cited by 436
Association of γ-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes
Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., & Thinakaran, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407986200 · Cited by 413
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Chapter 7 Protein Oxidation Processes in Aging Brain
Butterfield, D. A., & Stadtman, E. R. (1997) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60057-7 · Cited by 390
Self-citationThe Macrophage Cholesterol Exporter ABCA1 Functions as an Anti-inflammatory Receptor
Tang, C., Liu, Y., Kessler, P. S., Vaughan, A. M., & Oram, J. F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047472 · Cited by 284 · cited 1×
“ApoA-I inhibits TNF- release either by inhibition of the monocyte–macrophage contact interaction or by interaction with ABCA1 [13, 44].”
BackgroundSubramaniam, R., Roediger, F., Jordan, B., Mattson, M. P., Keller, J. N., Waeg, G., & Butterfield, D. A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031161.x · Cited by 270
Self-citationApolipoproteins: metabolic role and clinical biochemistry applications
Dominiczak, M. H., & Caslake, M. J. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011111 · Cited by 238
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188 · cited 1×
“DS patients have a high risk of developing AD [112] since the gene-encoding APP is localized on chromosome 21.”
BackgroundYamauchi, Y., Hayashi, M., Abe-Dohmae, S., & Yokoyama, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306258200 · Cited by 134
Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 1×
“The findings that ApoA-I binds to A [103], is present in senile plaques [104], and has been shown to prevent -sheet organization and A -iduced toxicity in vitro [105] strengthen a possible role of ApoA-I in AD pathology.”
BackgroundWang, L.-W., Tu, Y.-F., Huang, C.-C., & Ho, C.-J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-175 · Cited by 119
Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid
Golabek, A., Marques, M. A., Lalowski, M., & Wisniewski, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11565-7 · Cited by 99
Kurata, T., Miyazaki, K., Kozuki, M., Panin, V.-L., Morimoto, N., Ohta, Y., Nagai, M., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.067 · Cited by 98
Perluigi, M., di Domenico, F., Fiorini, A., Cocciolo, A., Giorgi, A., Foppoli, C., Butterfield, D. A., Giorlandino, M., Giorlandino, C., Eugenia Schininà, M., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000121 · Cited by 97 · cited 2×
“A recent study also showed a significant increase in oxidation markers in amniotic fluid of women carrying DS fetuses compared to that of women carrying chromosomally normal fetuses [117].”
BackgroundResultSelf-citationButterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
Self-citationKawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A. (1995) · Clinica Chimica Acta · doi:10.1016/0009-8981(95)06115-t · Cited by 68
Cited by
Wang, E.-S., Yao, H.-B., Chen, Y.-H., Wang, G., Gao, W.-W., Sun, Y.-R., Guo, J.-G., Hu, J.-W., Jiang, C.-C., & Hu, J. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350082 · Cited by 1,176
Erickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
Di Domenico, F., Tramutola, A., & Butterfield, D. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.490 · Cited by 253
Self-citationButterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.006 · Cited by 126
Self-citationCerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Metadata
- Authors
- Keeney, J. T. R., Swomley, A. M., Förster, S., Harris, J. L., Sultana, R., & Butterfield, D. A.
- Venue
- PROTEOMICS – Clinical Applications
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 7
- Issue
- 1-2
- Pages
- 109-122
- ISSN
- 1862-8346 (ISSN-L)
- 1862-8354
- OpenAlex
- W2000744762
- Cited by
- 72
- References
- 29
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.